Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Passeri

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Medicine|July 19, 2016
Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patientsFrancesca Ferretti, Alba Bigoloni, Laura Passeri, et al.
Science Translational Medicine|August 21, 2024
Microglia-specific <i>IL-10</i> gene delivery inhibits neuroinflammation and neurodegeneration in a mouse model of Parkinson's diseaseSimone Bido, Melania Nannoni, Sharon Muggeo, et al.
Journal of Autoimmunity|May 24, 2023
Tolerogenic IL-10-engineered dendritic cell-based therapy to restore antigen-specific tolerance in T cell mediated diseasesLaura Passeri, Grazia Andolfi, Virginia Bassi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 21, 2025
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World StudyFederica Lo Prinzi, Federico Rossari, Antonio De Rosa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2026
Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumabAndrea Casadei-Gardini, Terry Cheuk-Fung Yip, Alessandro Vitale, et al.
Targeted Oncology|February 27, 2026
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and DurvalumabSilvia Camera, Lorenzo Fornaro, Margherita Rimini, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 12, 2025
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International CentersMargherita Rimini, Lorenzo Fornaro, Masafumi Ikeda, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 17, 2025
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D IndexMara Persano, Margherita Rimini, Francesca Salani, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Medicine|July 19, 2016
Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patientsFrancesca Ferretti, Alba Bigoloni, Laura Passeri, et al.
Science Translational Medicine|August 21, 2024
Microglia-specific <i>IL-10</i> gene delivery inhibits neuroinflammation and neurodegeneration in a mouse model of Parkinson's diseaseSimone Bido, Melania Nannoni, Sharon Muggeo, et al.
Journal of Autoimmunity|May 24, 2023
Tolerogenic IL-10-engineered dendritic cell-based therapy to restore antigen-specific tolerance in T cell mediated diseasesLaura Passeri, Grazia Andolfi, Virginia Bassi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 21, 2025
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World StudyFederica Lo Prinzi, Federico Rossari, Antonio De Rosa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2026
Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumabAndrea Casadei-Gardini, Terry Cheuk-Fung Yip, Alessandro Vitale, et al.
Targeted Oncology|February 27, 2026
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and DurvalumabSilvia Camera, Lorenzo Fornaro, Margherita Rimini, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 12, 2025
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International CentersMargherita Rimini, Lorenzo Fornaro, Masafumi Ikeda, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 17, 2025
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D IndexMara Persano, Margherita Rimini, Francesca Salani, et al.
Pageof 2